Sinobiomed’s New U.S. Leadership Seeks Licensing Deals, Strategic Investment From Global Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Chinese firm’s board brings in a slate of U.S. execs to engineer a turnaround after Sinobiomed's valuation drops from $400 million to $10 million.